Advertisement
Screener

Ionis Pharmaceuticals, Inc. (IONS) Increase (Decrease) in Other Operating Assets

2.8 / 5 stars · 68/120 Roast Me

Ionis Pharmaceuticals, Inc. Increase (Decrease) in Other Operating Assets

Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Other Operating Assets of $38.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-07-29

  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $30.88M, a 203.59% increase year-over-year.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $7.39M, a 40.24% decline year-over-year.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$90.28M, a 609.98% decline year-over-year.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $100.95M.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2025 was $33.21M, a 28.44% increase from fiscal 2024.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2024 was $25.86M, a 23.42% decline from fiscal 2023.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2023 was $33.76M, a 23.97% increase from fiscal 2022.
  • Ionis Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2022 was $27.23M, a 3005.47% increase from fiscal 2021.
Period endIncrease (Decrease) in Other Operating Assets 3 monthIncrease (Decrease) in Other Operating Assets 3 month as first filedIncrease (Decrease) in Other Operating Assets 6 monthIncrease (Decrease) in Other Operating Assets 6 month as first filedIncrease (Decrease) in Other Operating Assets 9 monthIncrease (Decrease) in Other Operating Assets 9 month as first filedIncrease (Decrease) in Other Operating Assets 12 monthIncrease (Decrease) in Other Operating Assets 12 month as first filed
2026-06-30$30.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$38.27M
10-Q · filed 2026-07-29
-$52.01M
derived: sum of 3 quarters · filed 2026-07-29
$48.94M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$7.39M
10-Q · filed 2026-04-29
-$82.89M
derived: sum of 2 quarters · filed 2026-04-29
$18.07M
derived: sum of 3 quarters · filed 2026-04-29
$28.24M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31-$90.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$10.68M
derived: sum of 2 quarters · filed 2026-02-26
$20.85M
derived: sum of 3 quarters · filed 2026-07-29
$33.21M
10-K · filed 2026-02-26
2025-09-30$100.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$111.12M
derived: sum of 2 quarters · filed 2026-07-29
$123.49M
10-Q · filed 2025-10-29
$141.19M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$10.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$22.54M
10-Q · filed 2026-07-29
$40.24M
derived: sum of 3 quarters · filed 2026-07-29
$39.01M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$12.37M
10-Q · filed 2026-04-29
$30.07M
derived: sum of 2 quarters · filed 2026-04-29
$28.84M
derived: sum of 3 quarters · filed 2026-04-29
$49.27M
derived: sum of 4 quarters · filed 2026-04-29
2024-12-31$17.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$16.48M
derived: sum of 2 quarters · filed 2026-02-26
$36.91M
derived: sum of 3 quarters · filed 2026-02-26
$25.86M
10-K · filed 2026-02-26
2024-09-30-$1.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$19.20M
derived: sum of 2 quarters · filed 2025-10-29
$8.15M
10-Q · filed 2025-10-29
$23.59M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$20.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
$9.38M
10-Q · filed 2025-07-30
$24.82M
derived: sum of 3 quarters · filed 2026-02-26
$23.45M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$11.05M
10-Q · filed 2025-04-30
-$13.38M
10-Q · filed 2024-05-07
$4.39M
derived: sum of 2 quarters · filed 2026-02-26
$3.02M
derived: sum of 3 quarters · filed 2026-02-26
$28.03M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$15.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$14.07M
derived: sum of 2 quarters · filed 2026-02-26
$39.08M
derived: sum of 3 quarters · filed 2026-02-26
$33.76M
10-K · filed 2026-02-26
$29.84M
10-K · filed 2024-02-21
2023-09-30-$1.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$23.64M
derived: sum of 2 quarters · filed 2024-11-06
$18.32M
10-Q · filed 2024-11-06
$44.57M
derived: sum of 4 quarters · filed 2025-02-19
2023-06-30$25.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$19.70M
10-Q · filed 2024-08-01
$45.94M
derived: sum of 3 quarters · filed 2025-02-19
$46.89M
derived: sum of 4 quarters · filed 2025-02-19
2023-03-31-$5.31M
10-Q · filed 2024-05-07
$20.93M
derived: sum of 2 quarters · filed 2025-02-19
$21.88M
derived: sum of 3 quarters · filed 2025-02-19
$14.70M
derived: sum of 4 quarters · filed 2025-02-19
2022-12-31$26.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19
$27.20M
derived: sum of 2 quarters · filed 2025-02-19
$20.01M
derived: sum of 3 quarters · filed 2025-02-19
$27.23M
10-K · filed 2025-02-19
$24.68M
10-K · filed 2023-02-22
2022-09-30$949.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
-$6.23M
derived: sum of 2 quarters · filed 2023-11-02
$988.00K
10-Q · filed 2023-11-02
$12.22M
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30-$7.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$39.00K
10-Q · filed 2023-08-09
$11.27M
derived: sum of 3 quarters · filed 2024-02-21
$10.10M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31$7.22M
10-Q · filed 2023-05-03
$18.46M
derived: sum of 2 quarters · filed 2024-02-21
$17.28M
derived: sum of 3 quarters · filed 2024-02-21
$24.58M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$11.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
$10.06M
derived: sum of 2 quarters · filed 2024-02-21
$17.36M
derived: sum of 3 quarters · filed 2024-02-21
$877.00K
10-K · filed 2024-02-21
2021-09-30-$1.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$6.12M
derived: sum of 2 quarters · filed 2022-11-09
-$10.36M
10-Q · filed 2022-11-09
-$6.03M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30$7.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$9.18M
10-Q · filed 2022-08-09
-$4.85M
derived: sum of 3 quarters · filed 2023-02-22
$1.80M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31-$16.48M
10-Q · filed 2022-05-04
-$12.15M
derived: sum of 2 quarters · filed 2023-02-22
-$5.50M
derived: sum of 3 quarters · filed 2023-02-22
$3.03M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31$4.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$10.98M
derived: sum of 2 quarters · filed 2023-02-22
$19.51M
derived: sum of 3 quarters · filed 2023-02-22
$9.97M
10-K · filed 2023-02-22
2020-09-30$6.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$15.18M
derived: sum of 2 quarters · filed 2021-11-03
$5.65M
10-Q · filed 2021-11-03
$26.93M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$8.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
-$1.00M
10-Q · filed 2021-08-04
-$1.06M
10-Q · filed 2020-08-05
$20.28M
derived: sum of 3 quarters · filed 2022-02-25
$37.29M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31-$9.53M
10-Q · filed 2021-05-05
$11.75M
derived: sum of 2 quarters · filed 2022-02-25
$28.75M
derived: sum of 3 quarters · filed 2022-02-25
$36.45M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31$21.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$38.29M
derived: sum of 2 quarters · filed 2022-02-25
$45.98M
derived: sum of 3 quarters · filed 2022-02-25
$44.66M
10-K · filed 2022-02-25
2019-09-30$17.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
$24.70M
derived: sum of 2 quarters · filed 2020-11-04
$23.38M
10-Q · filed 2020-11-04
$26.15M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$7.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
$6.37M
10-Q · filed 2020-08-05
$9.15M
derived: sum of 3 quarters · filed 2021-02-24
$30.54M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31-$1.33M
10-Q · filed 2020-05-06
-$1.80M
10-Q · filed 2019-05-09
$1.45M
derived: sum of 2 quarters · filed 2021-02-24
$22.84M
derived: sum of 3 quarters · filed 2021-02-24
$39.44M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$2.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$24.17M
derived: sum of 2 quarters · filed 2021-02-24
$40.77M
derived: sum of 3 quarters · filed 2021-02-24
$29.35M
10-K · filed 2021-02-24
2018-09-30$21.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
$37.99M
derived: sum of 2 quarters · filed 2019-11-06
$26.57M
10-Q · filed 2019-11-06
$50.07M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$16.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$5.18M
10-Q · filed 2019-08-08
$28.68M
derived: sum of 3 quarters · filed 2020-03-02
$24.17M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$11.42M
10-Q · filed 2019-05-09
$12.08M
derived: sum of 2 quarters · filed 2020-03-02
$7.57M
derived: sum of 3 quarters · filed 2020-03-02
$32.87M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$23.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$19.00M
derived: sum of 2 quarters · filed 2020-03-02
$44.29M
derived: sum of 3 quarters · filed 2020-03-02
$58.37M
10-K · filed 2020-03-02
2017-09-30-$4.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
$20.79M
derived: sum of 2 quarters · filed 2018-11-06
$34.87M
10-Q · filed 2018-11-06
$33.24M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$25.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$39.37M
10-Q · filed 2018-08-07
$37.74M
derived: sum of 3 quarters · filed 2019-03-01
$35.19M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$14.08M
10-Q · filed 2018-05-07
$12.45M
derived: sum of 2 quarters · filed 2019-03-01
$9.90M
derived: sum of 3 quarters · filed 2019-03-01
$9.73M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31-$1.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$4.18M
derived: sum of 2 quarters · filed 2019-03-01
-$4.35M
derived: sum of 3 quarters · filed 2019-03-01
-$1.60M
10-K · filed 2019-03-01
-$1.66M
10-K · filed 2017-03-01
2016-09-30-$2.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
-$2.72M
derived: sum of 2 quarters · filed 2017-11-07
$26.00K
10-Q · filed 2017-11-07
$27.00K
10-Q · filed 2016-11-09
-$9.04M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30-$171.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$2.58M
10-Q · filed 2017-08-09
-$6.49M
derived: sum of 3 quarters · filed 2018-02-28
-$7.66M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$2.75M
10-Q · filed 2017-05-09
-$6.32M
derived: sum of 2 quarters · filed 2018-02-28
-$7.49M
derived: sum of 3 quarters · filed 2018-02-28
$4.69M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31-$9.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
-$10.23M
derived: sum of 2 quarters · filed 2018-02-28
$1.94M
derived: sum of 3 quarters · filed 2018-02-28
$4.39M
10-K · filed 2018-02-28
$4.32M
10-K · filed 2016-02-26
2015-09-30-$1.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
$11.01M
derived: sum of 2 quarters · filed 2016-11-09
$13.46M
10-Q · filed 2016-11-09
$13.26M
10-Q · filed 2015-11-09
$13.97M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$12.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
$14.63M
10-Q · filed 2016-08-09
$14.63M
10-Q · filed 2015-08-05
$15.14M
derived: sum of 3 quarters · filed 2017-03-01
$15.68M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$2.45M
10-Q · filed 2016-05-05
$2.96M
derived: sum of 2 quarters · filed 2017-03-01
$3.51M
derived: sum of 3 quarters · filed 2017-03-01
$3.31M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$511.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$1.05M
derived: sum of 2 quarters · filed 2017-03-01
$854.00K
derived: sum of 3 quarters · filed 2017-03-01
$1.75M
10-K · filed 2017-03-01
2014-09-30$544.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$343.00K
derived: sum of 2 quarters · filed 2015-11-09
$1.24M
10-Q · filed 2015-11-09
$795.00K
derived: sum of 4 quarters · filed 2016-02-26
2014-06-30-$201.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
$695.00K
10-Q · filed 2015-08-05
$694.00K
10-Q · filed 2014-08-04
$251.00K
derived: sum of 3 quarters · filed 2016-02-26
$1.29M
derived: sum of 4 quarters · filed 2016-02-26
2014-03-31$896.00K
10-Q · filed 2015-05-05
$452.00K
derived: sum of 2 quarters · filed 2016-02-26
$1.50M
derived: sum of 3 quarters · filed 2016-02-26
$386.00K
derived: sum of 4 quarters · filed 2016-02-26
2013-12-31-$444.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26
$599.00K
derived: sum of 2 quarters · filed 2016-02-26
-$510.00K
derived: sum of 3 quarters · filed 2016-02-26
$1.09M
10-K · filed 2016-02-26
2013-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07
-$66.00K
derived: sum of 2 quarters · filed 2014-11-07
$1.53M
10-Q · filed 2014-11-07
2013-06-30-$1.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04
$492.00K
10-Q · filed 2014-08-04
2013-03-31$1.60M
10-Q · filed 2014-05-06
2012-12-31-$279.00K
10-K · filed 2015-03-02
2011-12-31-$914.00K
10-K · filed 2014-03-03
2010-12-31$943.00K
10-K · filed 2013-02-28
2009-12-31$955.00K
10-K · filed 2012-02-29
2008-12-31$2.66M
10-K · filed 2011-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10